Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "Antibodies"

RheumMadness 2023: The Results Are In

David L. Leverenz, MD, MEd  |  September 11, 2023

RheumMadness is an online tournament in which a bracket of teams, representing key learning concepts in rheumatology, compete against each other in a series of head-to-head matchups, much like basketball teams in the NCAA’s March Madness. The 2023 tournament theme was The All Star Season. Each team represented one all star article competing to be…

Corona Borealis Studio / shutterstock.com

The Reliability & Utility of Serological Antibody Tests in COVID-19

Ruth Jessen Hickman, MD  |  September 11, 2020

Serological testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies may play a critical role in the management of the worldwide health crisis. Such testing may reveal key information for epidemiology, convalescent plasma therapies and vaccine development. However, the situation is complex, and much is unknown. Although such testing may ultimately be used to…

Malignant Complications: Screening for Cancer in Rheumatic Diseases

Jason Liebowitz, MD, FACR  |  July 13, 2020

Cancer and autoimmunity have a complex relationship. In a presentation, Ami Shah, MD, MHS, discussed how to use autoantibodies as tools for cancer risk stratification, how to approach cancer screening in individuals with new-onset disease and more…

Regeneron Plans Early Summer Trials for New Antibodies Against Coronavirus

Reuters Staff  |  March 18, 2020

(Reuters)—Regeneron Pharmaceuticals Inc. said on Tuesday it had identified hundreds of antibodies that could treat or prevent the coronavirus (COVID-19) and was preparing to begin clinical trials by early summer, sending the drugmaker’s shares up 12%. The company will select the top two antibodies to develop a “cocktail” treatment and scale up its manufacturing to…

Rheumatology Drug Updates: Infliximab Biosimilar Cross Reacts to Infliximab Antibodies

Michele B. Kaufman, PharmD, BCGP  |  August 11, 2016

Cross Reactions A recent study published online in March in the Annals of the Rheumatic Diseases investigated if the infliximab biosimilar (CT-P13, infliximab-dyyb), which is marketed in Europe as Inflectra and Remsima, can be safely and effectively substituted for infliximab (Remicade).1 Infliximab and its biosimilar are manufactured via the same process. Researchers set out to…

New Assays May Help in the Diagnosis & Management of Antiphospholipid Syndrome

Lara C. Pullen, PhD  |  July 18, 2016

A new study found that measuring the presence of additional antibodies specific for Domain I (aDI) of β2-glycoprotein (β2GPI) may improve the diagnosis of antiphospholipid syndrome. Based on their findings, researchers conclude that aDI tests may be a useful addition to, but not a replacement for, standard aβ2GPI tests…

Naturally Occurring Antibodies May Lead to New RA Therapies

From the College  |  December 1, 2010

A study published in the Journal of Immunology indicates that naturally occurring antibodies in the human immune system have the capacity to suppress inflammatory responses throughout the body. These antibodies may provide researchers an opportunity to develop new therapies for rheumatoid arthritis (RA) and other inflammatory conditions using similar pathways.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences